Drugs in Dev. Cardiology/Vascular Diseases
Phase II
France 
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : CellProthera
Deal Size : Undisclosed
Deal Type : Agreement
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
Details : ProtheraCytes is an autologous expanded CD34+ stem cell-based therapy aimed at improving heart failure event-free survival following a severe heart attack.
Product Name : Protheracytes
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 20, 2025
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : CellProthera
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ataciguat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Rancho Santa Fe Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countr...
Product Name : HMR1766
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : Ataciguat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Rancho Santa Fe Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : BioCardia
Deal Size : Undisclosed
Deal Type : Collaboration
CellProthera and BioCardia Collaborate on Phase II ProtheraCytes™ Trial for AMI
Details : The collaboration aims to support the advancement of the mid-stage clinical trial product ProtheraCytes, which is being evaluated for the treatment of acute myocardial infarction led by CellProthera.
Product Name : Protheracytes
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 07, 2024
Lead Product(s) : Protheracytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : BioCardia
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : University of Birmingham
Deal Size : Undisclosed
Deal Type : Partnership
Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
Details : Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus.
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Undisclosed
November 22, 2022
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : University of Birmingham
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : TP ICAP Midcap
Deal Size : $10.0 million
Deal Type : Public Offering
Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
Details : TOTUM•070 is a combination of plant extracts, with no phytosterol or red yeast rice content. TOTUM•070 is being developed with a view to obtaining a proprietary health claim relating to the reduction of blood LDL cholesterol, a risk factor for cardio...
Product Name : Totum•070
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
September 11, 2022
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : TP ICAP Midcap
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This innovative study is the first to characterize the metabolites of TOTUM•070 in humans and their mode of action in the liver in a population of 10 healthy volunteers. TOTUM•070 was tested at its clinical daily dose (5g), used also in the Phase II ...
Product Name : Totum•070
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valbiotis Authorized to Launch HEART for TOTUM-070 to treat High Blood LDL-Cholesterol Levels
Details : The main objective of this clinical study is to evaluate the efficacy of a 5g daily dose of TOTUM-070 and to confirm its safety. HEART results will support the application for a proprietary health claim related to the reduction of LDL-cholesterol.
Product Name : Totum•070
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 15, 2021
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The clinical study HEART on TOTUM-070, a Phase II randomized placebo-controlled and double blind study, has just been initiated in accordance with the road map, the study protocol having been submitted to the French health authorities.
Product Name : Totum•070
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This Dose Escalation Phase of Glenzocimab as Add-on to Thrombolysis and/or Mechanical Thrombectomy was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy).
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Inapplicable
January 10, 2020
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
